|
|
News Breaks | | | | November 16, 2012 | | 08:06 EDT |  | GENE | Genetic Technologies downgraded to Sell from Buy at Ladenburg
Ladenburg downgraded Genetic Technologies two notches to Sell based on concerns it will not be able to secure patent license agreements due to the current patent landscape following the Mayo v Prometheus decision and the July 2012 USPTO decision to reexamination GENE’s ‘179 patent. As a result, the firm sees limited revenue contribution from its pipeline near-term. Price target cut to $1.60 from $7.50. | |
|
News For GENE From The Last 14 Days Check below for free stories on GENE the last two weeks. |
|
|
| May 20, 2013 | | 06:09 EDT |  | GENE | Genetic Technologies executes agreement with MultiPlan
 Subscribe for More Information | |
|
|
|
|
|
|
